• Search

Human iPSC-Derived Ventricular Cardiomyocytes (Female)

All Axol's cardiomyocytes are derived from human iPSCs and ONLY human iPSCs. We do NOT use animal cells or embryonic stem cells (ESCs).

Axol Bioscience; Quality Cells, Consistent Results, a brand you can trust.
Product Code: ax2502 Categories: , .

Payment Options

We accept Visa and MasterCard in our online store.

Worldwide Shipping

We can get your purchases to you wherever you are.

Customer Care

As an Axol customer you have access to our support team and product specialists.


Human iPSC-Derived Ventricular Cardiomyocytes (female) (1 million cells)

Product Specification

Ethnicity Asian
Starting material Peripheral blood mononuclear cells (PBMCs)
Donor gender Female
Donor age at sampling 42 yrs
Karyotype Normal
Reprogramming method Sendai virus
Genetic modification None
Size 1 million cells
Growth properties Adherent
Shipping conditions Dry ice
Storage conditions vapour phase nitrogen

Frequently Asked Questions

Yes, please follow the link here: https://www.axolbio.com/page/how-to-mea-atrial-and-ventricular-cardiomyocytes

ax2502 is derived from a female 42 year-old donor's PBMCs and Sendai virus reprogramming is used for generating its parental iPSC line. ax2505 is derived from CD34+ cord blood cells (male) that were reprogrammed using episomal vectors. These iPSCs have been used to generate ax0015 (iPSC-derived Neural Stem Cells), ax2115 (iPSC-derived Renal Proximal Tubular Cells) and ax0055 (iPSC-derived Sensory Neuron Progenitors). ax2520 is derived from CD34+ cord blood cells (male) that were reprogrammed using episomal vectors under current good manufacturing practice (cGMP) conditions. From the master stock of cGMP iPSCs a non-GMP, research grade working bank of iPSCs was created. Axol has then differentiated these research grade iPSCs into ventricular cardiomyocytes, this means that these cells are ideal for pre-clinical research as the iPSCs from cGMP are available for future clinical work. Please see publication below for information on this line of iPSCs: Baghbaderani BA, Tian X, Neo BH, et al. cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications. Stem Cell Reports (2015)

1. At the resuspension step, using P1000 and 1ml of plating medium to pipette up and down at least 5 times gently against the falcon tube which would partially disintegrate the aggregates; 2. In the counting step do not count the large aggregates and seed the culture vessel at a density of 50,000 cells/cm2 as instructed by the protocol; 3. The day after plating (Day 1), change Plating Medium to Cardiomocyte Maintenance Medium which would remove debris and cells that didn't attach (including large aggregates). 4. Using the recommended seeding density we have achieved over 70% confluence culture after plating.

No, you may passage within 3 days of plating to change culture vessel, but this is not recommended.

No, because the extra freeze/thaw cycle would effect the viability of the cells.

Technical Resources